Financial Report: AbbVie

AbbVie
 
3Q Revenues: $5.9 billion (+18)

3Q Earnings: $1.2 billion  (earnings were $506 million 3Q14)

YTD Revenues: $16.5 billion (+13%)

YTD Earnings: $3.6 billion (+41%)

Comments: Growth was driven by the continued strength of HUMIRA, up 12% to $3.6 billion in the quarter. IMBRUVICA sales were $304 million and VIEKIRA sales were $469 million in the quarter. Duodopa, Creon and Lupron sales were up 9%, 8%, and 2% respectively, while Kaletra sales declined 34% to $168 million, AndroGel sales were down 24% to $177 million, and Synagis sales were down 15% to $93 million. R&D expenses were $1.4 billion in the quarter, up from 812 million in 3Q14.